Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
Nature Medicine
|
January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responses
Noushin Niknafs, Archana Balan, Christopher Cherry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 4, 2018
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
Karthik Suresh, Kevin J Psoter, Khinh Ranh Voong, et al.
Cancer Research Communications
|
February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC
Mari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
JTO Clinical and Research Reports
|
November 8, 2021
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
Joshua E Reuss, Emily Brigham, Kevin J Psoter, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability
Yujie Zhao, Jarushka Naidoo, Michael Conroy, et al.
European Review for Medical and Pharmacological Sciences
|
May 18, 2021
Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy
M Lugara, G Oliva, P C Pafundi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
J W Riess, H A Yu, X Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2018
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh, Khinh Ranh Voong, Bairavi Shankar, et al.
Pharmacoepidemiology and Drug Safety
|
November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer
Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
Nature Medicine
|
January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responses
Noushin Niknafs, Archana Balan, Christopher Cherry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 4, 2018
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
Karthik Suresh, Kevin J Psoter, Khinh Ranh Voong, et al.
Cancer Research Communications
|
February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC
Mari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
JTO Clinical and Research Reports
|
November 8, 2021
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
Joshua E Reuss, Emily Brigham, Kevin J Psoter, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability
Yujie Zhao, Jarushka Naidoo, Michael Conroy, et al.
European Review for Medical and Pharmacological Sciences
|
May 18, 2021
Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy
M Lugara, G Oliva, P C Pafundi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
J W Riess, H A Yu, X Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2018
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh, Khinh Ranh Voong, Bairavi Shankar, et al.
Pharmacoepidemiology and Drug Safety
|
November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer
Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Page
of 11